⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PDSB News
PDS Biotechnology Corporation Common Stock
Correction: Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
GMAB
IMUX
INO
PDSB
AZN
GSK
MRK
BIIB
EXEL
REGN
CUE
IOBT
RAPT
PRE
Head and Neck Squamous Cell Carcinoma Market is Projected to Boost at a CAGR of 10.5% During the Forecast Period (2026–2036) Due to the Launch of Emerging Novel Immunotherapies | DelveInsight
globenewswire.com
JNJ
BNTX
CUE
GMAB
IMPP
INO
AZN
GSK
MRK
BMY
EXEL
REGN
PDSB
IOVA
RPTX
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB
PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update
globenewswire.com
PDSB
PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results
globenewswire.com
PDSB
Form 8-K
sec.gov
PDSB
Form 8-K
sec.gov
PDSB